Vivani's NPM-119 trial on clinical hold; submits Complete Response to FDA

Vivani Medical, Inc.

FDA placed LIBERATE-1 study on clinical hold Aug 11, citing insufficient CMC information to assess human subject risks.
Vivani submitted Complete Response on Aug 25; FDA has 30 days to respond.
If hold lifted, Phase 2a trial expected to start Oct 2023, interim results 1H2024, top-line 2H2024.
If CR inadequate, timeline delayed by ~one quarter.
Cortigent subsidiary to repay $1.5M and issue $2M promissory note at 5% under amended funding agreement.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vivani Medical, Inc. amended Amendment with Cortigent, Inc. valued at $1,500,000 (effective 2023-08-25).

Action: amendment
Agreement: credit facility
Counterparty: Cortigent, Inc.
Value: $1,500,000
Effective: 2023-08-25

Exact text from the filing

On August 25, 2023, the Company and Cortigent, Inc. ("Cortigent"), a wholly owned subsidiary of the Company entered into an Amendment 1 (the "Amendment") to the Transition Funding, Support and Services Agreement dated March 19, 2023 (the "TFSSA").

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Vivani Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001753926-23-001153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.